Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents

American Journal of Tropical Medicine and Hygiene

Volumn 66, Issue 5, 2002, Pages 516-525

  Li, Q G ^a   Mog, S R ^a   Si, Y Z ^a   Kyle, D E ^a   Gettayacamin, M ^a   Milhous, W K ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEETHER; CREMOPHOR; DIHYDROARTEMISININ; SESAME SEED OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; INJECTION SITE; MALARIA; MALE; NEUROTOXICITY; NONHUMAN; PLASMODIUM BERGHEI; RAT; SCORING SYSTEM;

ANIMALIA; PLASMODIUM BERGHEI; RODENTIA; SESAMUM INDICUM;

EID: 0036561429     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.66.516     Document Type: Article

References (61)

1. Fatal neurotoxicity of arteether and artemether
2. Arteether neurotoxicity in the absence of deficits in behavioural performance in rats
3. Artemisinin neurotoxicity: Neuropathology in rats and mechanistic studies in vitro
4. Arteether: Risks of two-week administration in Macaca mulatta
5. Studies of the neurotoxicity of oral artemisinin derivatives in mice
6. Arteether pharmacokinetics in rats after 25 mg/kg/day single and multiple doses
7. Differental effects of orally versus parenterally administered qinghaosu derivatives artemether in dogs
8. Dutch regiatration for artemotil injections
9. Arteether administration in humans: Preliminary studies of pharmacokinetics, safety and tolerance
10. Factors relating to neurotoxicity of artemisinin antimalarial drugs: Listening to arteether
11. Behavioral and neural toxicity of arteether but not artesunate or artelinate, in rats
12. Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice
13. Multiple dose pharmacokinetics of artemether in Chinese patients treated for falciparum malaria
14. Multiple dose pharmacokinetics of artemether in Chinese patients treated for falciparum malaria
15. Evidence for time-dependence artemisinin kinetics in adults with uncomplicated malaria
16. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults
17. Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for falciparum malaria
18. Safety assessment of peroxide antimalarials: Clinical and chemical perspectives
19. Neurotoxicity in animals due to arteether and artemether
20. Anorectic toxicity of dihydroartemisinin, artemether and arteether in rats following multiple intramuscular doses
21. Neurochemical mechanism of action of anorectic drugs
22. Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophore-EL
23. The effects of cremophore EL in the anaesthetized dog
24. Nursing implications in the administration of paclitaxel (TAXOL)
25. Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation
26. Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats
27. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
28. Amphetamine enantiomers and rat consummatory behavior: A new perspective
29. Bioavailabilty and pharmacokinetics of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats
30. Qinghaosu (artemisinin): An antimalarial drug from China
31. Arteether, a new antimalarial drug; synthesis and antimalarial properties
32. Efficacy of alpha, beta-arteether in acute uncomplicated P. falciparum malaria
33. Absorption, metabolism, and other factors that influence drug exposure in toxicology studies
34. Effects of initial body weight on anorexia and tolerance to fenfluramine in rats
35. The relationship between premorbid body weight, weight loss, and weight at referral in adolescent patients with anorexia nervosa
36. Relationship of body energy status to inflammation-induced anorexia and weight loss
37. Behavioral and neural toxicity of arteether in rats
38. Acute high dose arteether toxicity in rats
39. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria
40. A trial of artemether or quinine in children with cerebral malaria
41. Concentration and time dependence of artemisinin efficacy against Plasmodium falciparum in vitro
42. Plasmodium falciparum: In vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria
43. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs
44. Treatment of malaria: Some considerations and limitations of the current methods of assessment
45. Exposure and risk assessment with respect to contaminated soil: Significance of biomarkers and bioavailability
46. Dose and time as variable of toxicity
47. Dose-dependent brainstem neuropathology following repeated arteether administration in rats
48. Neurotoxicity and artemisinin compounds do the observations in animals justify limitation of clinical use?
49. Absorption, distribution, and excretion of toxicants
50. Dictyocaulus viviparous: Migration in agar of larvae subjected to a variety of physicochemical exposure
51. Quantitative definition of toxicity: A mathematical description of life and death with dose and time as variables
52. Pharmacokinetics of artemisinin-type compounds
53. In vitro neurotoxicity of artemisinin derivatives
54. The rational use of qinghaosu and its derivatives: What is the future of new compounds?
55. A randomized controlled trial of artemotil (β-arteether) in Zambian children with cerebral malaria
56. Clinical trial of beta-arteether versus quinine for the treatment of cerebral malaria in children in Yaounde, Cameroon